Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,238,152	$ 46,329,359
Short-term investments	195,513,005	206,669,397
Accounts receivable	73,304	1,701,726
Accounts receivable from affiliated entities	4,961,802	10,036,490
Prepaid expenses and other current assets	4,914,313	50,130,481
Prepaid expenses and other current assets from affiliated entities	195,853	375,227
Total current assets	233,896,429	315,242,680
Fixed assets, net	6,983,305	7,727,997
Investment in affiliated entity	2,623,781	2,007,142
Intangible assets, net	2,047,778	2,129,861
Goodwill	10,513,371	10,513,371
Operating lease right-of-use assets	9,865,543	10,228,207
Other assets	652,517	684,044
Total assets	266,582,724	348,533,302
Current liabilities:
Accounts payable and accrued expenses	24,752,171	79,686,885
Accounts payable and accrued expenses due to affiliated entities	1,417,274	1,220,439
Accrued clinical trial expenses	5,795,846	10,594,073
Operating lease liability	2,579,949	2,803,973
Grant funding liability	4,121,989	2,475,031
Grant funding liability from affiliated entity	89,007	87,673
Convertible senior notes	16,394,841	0
Total current liabilities	55,151,077	96,868,074
Convertible senior notes	0	16,614,840
Operating lease liability, net of current portion	12,185,919	12,655,586
Deferred tax liabilities	32,046	32,046
Total liabilities	67,369,042	126,170,546
Stockholders’ equity:
Preferred stock	0	0
Common stock	262,738	253,090
Additional paid-in capital	1,728,030,842	1,710,656,191
Accumulated deficit	(1,528,497,101)	(1,487,847,784)
Accumulated other comprehensive loss	(582,797)	(698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	199,213,682	222,362,756
Total liabilities and stockholders’ equity	$ 266,582,724	$ 348,533,302